Payment overview · 2025
General Payments
$617.77
28 reported records · 12 companies
Healthcare provider profile · identity verified
Karla D Hostetler, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · NEWTON, KS · NPI 1669436366
Verified facts
What the public records show
CMS Open Payments records show Karla D Hostetler, APRN received $617.77 in general payments during 2025 across 28 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $157.75 | 25.5% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$96.18 | 15.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $71.28 | 11.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.02 | 10.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.02 | 9.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.46 | 6.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.33 | 4.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.60 | 4.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.50 | 4.0% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $21.57 | 3.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.86 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.20 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $617.77 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $109.77 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $97.73 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $96.18 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $57.65 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $57.65 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $57.65 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $50.83 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $47.98 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $44.55 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.46 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.06 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 44 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
228 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 517 | 75 |
| Famotidine | Famotidine | 502 | 57 |
| Potassium Chloride | Potassium Chloride | 447 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 443 | 79 |
| Losartan Potassium | Losartan Potassium | 423 | 64 |
| Omeprazole | Omeprazole | 412 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 385 | 63 |
| Sertraline Hcl | Sertraline Hcl | 370 | 41 |
| Furosemide | Furosemide | 360 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 314 | 44 |
| Lisinopril | Lisinopril | 302 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 282 | 58 |
| Donepezil Hcl | Donepezil Hcl | 255 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 255 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 27 |
| Gabapentin | Gabapentin | 239 | 39 |
| Eliquis | Apixaban | 228 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 218 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 196 | 26 |
| Metformin Hcl | Metformin Hcl | 177 | 35 |
| Trazodone Hcl | Trazodone Hcl | 170 | 31 |
| Simvastatin | Simvastatin | 164 | 24 |
| Bupropion Xl | Bupropion Hcl | 145 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 15 |
| Cephalexin | Cephalexin | 142 | 53 |
| Mirtazapine | Mirtazapine | 140 | 16 |
| Tramadol Hcl | Tramadol Hcl | 140 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 30 |
| Carvedilol | Carvedilol | 130 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 124 | 16 |
| Fentanyl | Fentanyl | 121 | suppressed |
| Prednisone | Prednisone | 120 | 48 |
| Lorazepam | Lorazepam | 111 | 18 |
| Gemtesa | Vibegron | 97 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 96 | 14 |
| Propranolol Hcl | Propranolol Hcl | 93 | suppressed |
| Celecoxib | Celecoxib | 88 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 86 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 28 |
| Memantine Hcl | Memantine Hcl | 82 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 81 | suppressed |
| Myrbetriq | Mirabegron | 78 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 11 |
| Bumetanide | Bumetanide | 71 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 68 | suppressed |
| Meloxicam | Meloxicam | 68 | 20 |
| Alendronate Sodium | Alendronate Sodium | 67 | 23 |
| Torsemide | Torsemide | 67 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 66 | suppressed |
| Ozempic | Semaglutide | 66 | 12 |
| Dutasteride | Dutasteride | 65 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 65 | 15 |
| Levetiracetam | Levetiracetam | 63 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 62 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 61 | suppressed |
| Atenolol | Atenolol | 60 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 58 | suppressed |
| Pregabalin | Pregabalin | 58 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 55 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 54 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 53 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 53 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 53 | 12 |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Topiramate | Topiramate | 50 | suppressed |
| Alprazolam | Alprazolam | 49 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | suppressed |
| Amoxicillin | Amoxicillin | 48 | 31 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Primidone | Primidone | 46 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Jardiance | Empagliflozin | 44 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 40 | suppressed |
| Spironolactone | Spironolactone | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 33 |
| Allopurinol | Allopurinol | 37 | suppressed |
| Loperamide | Loperamide Hcl | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 11 |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Nystatin | Nystatin | 33 | 18 |
| Telmisartan | Telmisartan | 33 | suppressed |
| Estradiol | Estradiol | 32 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 12 |
| Clonazepam | Clonazepam | 31 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 30 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 12 |
| Temazepam | Temazepam | 27 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 12 |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Nystop | Nystatin | 26 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 21 |
| Azithromycin | Azithromycin | 22 | 19 |
| Digoxin | Digoxin | 22 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 22 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Mesalamine Dr | Mesalamine | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 16 | 13 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Acyclovir | Acyclovir | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 14 |
| Fluconazole | Fluconazole | 14 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Qulipta | Atogepant | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $617.77 · 28 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BEXSERO, BREZTRI, COMIRNATY, EVENITY, FARXIGA, FREESTYLE LIBRE 3, INTELLIS ADAPTIVESTIM, JARDIANCE, KISUNLA, MOUNJARO, NURTEC ODT, Omnipod, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REXULTI, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error